Ascelia Pharma Provides Orviglance(R) Update Following FDA Type a Meeting ...
(PR-inside.com) MALMÖ, SE / ACCESS Newswire / October 11, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) today announces that it has received the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) issued for the Orviglance® …
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Cancele cuando quiera · 99 CA$/mes


